IOL Chemicals

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE485C01029
  • NSEID: IOLCP
  • BSEID: 524164
INR
77.40
5.8 (8.1%)
BSENSE

Mar 24

BSE+NSE Vol: 59.32 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

59.32 lacs (178.64%) Volume

Shareholding (Dec 2025)

FII

2.08%

Held by 59 FIIs

DII

0.01%

Held by 1 DIIs

Promoter

52.62%

When is the next results date for IOL Chemicals?

06-Jun-2025

No Upcoming Board Meetings

What does IOL Chemicals do?

06-Jun-2025

IOL Chemicals and Pharmaceuticals Ltd specializes in Active Pharmaceutical Ingredients (APIs) and specialty chemicals, with a market cap of Rs 2,609 Cr and reported net sales of 528 Cr and net profit of 31 Cr for Q1 2025. The company, established in 1986, operates in the Pharmaceuticals & Biotechnology industry.

Overview:<BR>IOL Chemicals and Pharmaceuticals Ltd is a prominent player in the Active Pharmaceutical Ingredient (API) and specialty chemicals sectors, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap company.<BR><BR>History:<BR>Incorporated in September 1986, IOL Chemicals has established itself in the pharmaceutical sector. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 528 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 31 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 2,609 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 25.00<BR>- Industry P/E: 47<BR>- Dividend Yield: 0.91%<BR>- Debt Equity: -0.06<BR>- Return on Equity: 5.99%<BR>- Price to Book: 1.51<BR><BR>Contact Details:<BR>Address: Trident Complex, Raikot Road Barnala Sangrur Punjab : 148101<BR>Tel: 91-01679-244701-07<BR>Email: contact@iolcp.com<BR>Website: http://www.iolcp.com

View full answer

Who are in the management team of IOL Chemicals?

06-Jun-2025

As of March 2023, the management team of IOL Chemicals includes Varinder Gupta (Managing Director), Vikas Gupta (Joint Managing Director), Kushal Kumar Rana (Director), Abhiraj Gupta (Executive Director), and Abhay Raj Singh (Company Secretary). The board also features independent directors such as Rajender Mohan Malla (Chairman), Sandhya Mehta, Harpal Singh, and Sharad Tyagi.

As of March 2023, the management team of IOL Chemicals includes the following individuals:<BR><BR>1. Varinder Gupta - Managing Director<BR>2. Vikas Gupta - Joint Managing Director<BR>3. Kushal Kumar Rana - Director (Works)<BR>4. Abhiraj Gupta - Executive Director<BR>5. Abhay Raj Singh - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several independent and non-executive directors, including:<BR>- Sandhya Mehta - Non-Executive & Independent Director<BR>- Rajender Mohan Malla - Chairman & Independent Director<BR>- Harpal Singh - Non-Executive & Independent Director<BR>- Sharad Tyagi - Independent Director<BR><BR>This team is responsible for the strategic direction and governance of the company.

View full answer

Who are the peers of the IOL Chemicals?

03-Jun-2025

IOL Chemicals' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Novartis India, Indoco Remedies, Senores Pharma, SMS Pharma, and Syncom Formul. While IOL Chemicals has average management risk and a 1-year return of 23.27%, its growth is below average compared to its peers.

Peers: The peers of IOL Chemicals are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Novartis India, Indoco Remedies, Senores Pharma., SMS Pharma, and Syncom Formul.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Torrent Pharma, Dr Reddy's Labs, and the rest. Average management risk is found at IOL Chemicals, Novartis India, Indoco Remedies, SMS Pharma, and the rest. Below Average management risk is noted for Senores Pharma. Growth is excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest, while IOL Chemicals, Divi's Lab., Indoco Remedies, Torrent Pharma, SMS Pharma, and the rest show below average growth. Good growth is seen at Novartis India, and Senores Pharma. has excellent growth. Capital structure is excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, IOL Chemicals, Novartis India, and the rest, while average capital structure is found at Indoco Remedies and SMS Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Novartis India has the lowest at -3.58%. IOL Chemicals has a 1-year return of 23.27%, which is higher than Novartis India but lower than Divi's Lab. Additionally, Indoco Remedies and SMS Pharma have negative six-month returns.

View full answer

Is IOL Chemicals overvalued or undervalued?

09-Jun-2025

As of May 19, 2025, IOL Chemicals is considered very expensive and overvalued compared to its peers, with key financial ratios significantly higher and lower returns, making it an unfavorable investment despite a recent strong performance.

As of 19 May 2025, the valuation grade for IOL Chemicals has moved from fair to very expensive. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 25.73, an EV to EBITDA of 12.39, and a Price to Book Value of 1.54, which are significantly higher than many of its peers.<BR><BR>In comparison, Solar Industries has a PE ratio of 123.77 and an EV to EBITDA of 76.22, while Godrej Industries, which is rated attractive, has a PE ratio of 46.63 and an EV to EBITDA of 34.36. These comparisons highlight that IOL Chemicals is not only overvalued relative to its peers but also lacks competitive returns, with a ROE of 5.99% and a ROCE of 8.18%. Despite a strong 1-month return of 42.94% compared to the Sensex's 3.88%, the overall valuation indicates that IOL Chemicals is not a favorable investment at this time.

View full answer

Who are the top shareholders of the IOL Chemicals?

17-Jul-2025

The top shareholders of IOL Chemicals include Maya Devi Polycot Limited with 21.54%, Vasudeva Commercials Limited at 7.94%, and individual investors holding 31.43%. Mutual funds hold 0.02%, while Foreign Institutional Investors (FIIs) account for 1.47%.

The top shareholders of IOL Chemicals include the promoters, who hold a significant majority. The promoter with the highest holding is Maya Devi Polycot Limited, which owns 21.54% of the shares. Additionally, the highest public shareholder is Vasudeva Commercials Limited, holding 7.94%. Individual investors collectively hold 31.43% of the shares, while mutual funds have a minor stake through six schemes, accounting for 0.02%. Foreign Institutional Investors (FIIs) hold 1.47% of the company through 47 different entities.

View full answer

How big is IOL Chemicals?

24-Jul-2025

As of 24th July, IOL Chemicals & Pharmaceuticals Ltd has a market capitalization of 2,894.00 Cr, with recent net sales of 2,079.21 Cr and a net profit of 101.07 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: IOL Chemicals & Pharmaceuticals Ltd has a market capitalization of 2,894.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2,079.21 Cr, while the sum of Net Profit for the same period is 101.07 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2024. Shareholder's Funds are valued at 1,611.51 Cr, and Total Assets amount to 2,244.40 Cr.

View full answer

Is IOL Chemicals technically bullish or bearish?

10-Oct-2025

As of October 9, 2025, IOL Chemicals exhibits a mildly bullish trend supported by MACD and Bollinger Bands, though tempered by a mildly bearish KST and Dow Theory signals on the weekly chart.

As of 9 October 2025, the technical trend for IOL Chemicals has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by weekly and monthly MACD indicators both showing bullish signals. The Bollinger Bands also reflect a mildly bullish trend in both time frames. However, the KST indicates a mildly bearish stance on the weekly chart, and Dow Theory shows a mildly bearish trend on the weekly level with no trend on the monthly. The daily moving averages are mildly bullish, but the overall strength is tempered by the recent price action, including a decline from the previous close.

View full answer

Are IOL Chemicals latest results good or bad?

12-Nov-2025

IOL Chemicals' latest results show strong year-on-year growth, with a 56.50% increase in net profit and record revenue of ₹567.53 crores. However, there are concerns due to an 11.67% decline in net profit from the previous quarter and contracting operating margins, indicating potential challenges ahead.

IOL Chemicals' latest results present a mixed picture. On one hand, the company achieved a significant year-on-year increase in net profit, which surged by 56.50% to ₹29.97 crores compared to the same quarter last year. Additionally, revenue reached an all-time high of ₹567.53 crores, reflecting a 7.95% increase year-on-year and a 2.87% growth quarter-on-quarter.<BR><BR>However, the sequential performance raises concerns. The net profit declined by 11.67% from the previous quarter, which indicates potential challenges in maintaining profitability. Operating margins also contracted, falling from 11.26% in the previous quarter to 10.06%, suggesting pressure on margins despite the revenue growth.<BR><BR>Overall, while the year-on-year results are strong and indicate operational improvements, the sequential decline in profit and margins points to underlying issues that could affect sustainability. Investors should keep an eye on these trends to assess the company's future performance.

View full answer

How has been the historical performance of IOL Chemicals?

12-Nov-2025

IOL Chemicals has experienced a declining trend in net sales and profits over the past few years, with net sales dropping from 2,217.11 Cr in March 2023 to 2,079.21 Cr in March 2025, and profit after tax decreasing from 134.43 Cr to 101.07 Cr in the same period. Despite this, total assets increased to 2,382.07 Cr in March 2025.

Answer:<BR>The historical performance of IOL Chemicals shows a declining trend in net sales and profits over the past few years.<BR><BR>Breakdown:<BR>IOL Chemicals reported net sales of 2,079.21 Cr in March 2025, down from 2,132.79 Cr in March 2024 and 2,217.11 Cr in March 2023, indicating a consistent decrease in revenue. Total operating income mirrored this decline, with figures of 2,079.21 Cr in March 2025 compared to 2,132.79 Cr in the previous year. The total expenditure, excluding depreciation, also decreased to 1,876.91 Cr in March 2025 from 1,902.20 Cr in March 2024. Operating profit (PBDIT) fell to 224.71 Cr in March 2025, down from 260.66 Cr in March 2024, while profit before tax decreased to 137.96 Cr from 181.65 Cr. Consequently, profit after tax was 101.07 Cr in March 2025, a decline from 134.43 Cr in March 2024. The company's total assets increased to 2,382.07 Cr in March 2025 from 2,244.40 Cr in March 2024, while total liabilities also rose to 2,382.07 Cr from 2,244.40 Cr. Cash flow from operating activities was 178.00 Cr in March 2025, down from 289.00 Cr in March 2024, but net cash inflow improved to 70.00 Cr from 6.00 Cr. Overall, the financial metrics reflect a challenging period for IOL Chemicals, characterized by declining sales and profits despite an increase in total assets.

View full answer

Should I buy, sell or hold IOL Chemicals & Pharmaceuticals Ltd?

13-Feb-2026

Has IOL Chemicals & Pharmaceuticals Ltd declared dividend?

13-Feb-2026

Yes, IOL Chemicals & Pharmaceuticals Ltd has declared a 50% dividend, amounting to ₹4 per share, with an ex-date of February 18, 2025. Despite recent volatility, the company has shown positive total returns over the 1-year (8.15%) and 3-year (35.53%) periods.

IOL Chemicals & Pharmaceuticals Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 4<BR>- Ex-date: Feb-18-2025<BR><BR>Dividend Yield: 1.05%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was -23.6%, the dividend return was 1.05%, resulting in a total return of -22.55%.<BR><BR>Over the past 6 months, the price return was -20.07%, the dividend return was 1.06%, leading to a total return of -19.01%.<BR><BR>In the 1-year period, the price return was 6.64%, the dividend return was 1.51%, culminating in a total return of 8.15%.<BR><BR>For the 2-year period, the price return was -6.18%, the dividend return was 6.07%, resulting in a total return of -0.11%.<BR><BR>In the last 3 years, the price return was 18.32%, the dividend return was 17.21%, which led to a total return of 35.53%.<BR><BR>Over the 4-year period, the price return was -7.45%, the dividend return was 21.63%, resulting in a total return of 14.18%.<BR><BR>In the 5-year span, the price return was -44.32%, the dividend return was 16.35%, leading to a total return of -27.97%.<BR><BR>Overall, IOL Chemicals & Pharmaceuticals Ltd has declared a substantial dividend, and while the recent total returns have shown volatility, the company has managed to provide positive returns over longer periods, particularly in the 1-year and 3-year spans.

View full answer

Why is IOL Chemicals & Pharmaceuticals Ltd falling/rising?

17-Mar-2026

As of 17-Mar, IOL Chemicals & Pharmaceuticals Ltd's stock price is declining at 68.21, down 0.41% and has fallen for five consecutive days, totaling a 6.01% drop. The stock is underperforming both its sector and the market, with weak long-term growth prospects contributing to negative investor sentiment.

As of 17-Mar, IOL Chemicals & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 68.21, which reflects a change of -0.28 (-0.41%). The stock has been underperforming, having fallen for the last five consecutive days, resulting in a total decline of 6.01% over that period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>In terms of performance relative to the market, the stock has also underperformed its sector by 0.4% today. Year-to-date, the stock has dropped 17.07%, while the benchmark index, Sensex, has only decreased by 10.74%. This suggests that the stock is not only falling but doing so at a rate greater than the overall market.<BR><BR>Despite some positive financial indicators, such as a 33.32% growth in profit after tax and record net sales in the last quarter, the long-term growth prospects appear weak. Over the past five years, net sales have only grown at an annual rate of 0.38%, and operating profit has increased by 7.22%. This lack of robust long-term growth may contribute to investor sentiment that is cautious or negative.<BR><BR>Moreover, the low stake held by domestic mutual funds, at just 0.04%, may indicate a lack of confidence in the stock's valuation or business prospects. This could further exacerbate the downward pressure on the stock price. <BR><BR>Overall, the combination of recent poor performance, negative investor sentiment, and weak long-term growth prospects are contributing to the decline in IOL Chemicals & Pharmaceuticals Ltd's stock price.

View full answer

Why is IOL Chemicals & Pharmaceuticals Ltd falling/rising?

18-Mar-2026

As of 18-Mar, IOL Chemicals & Pharmaceuticals Ltd's stock price has risen to 73.76, up 8.14%, driven by a trend reversal after prior declines, increased investor interest, and strong financial results, including a 48.50% growth in profit. The stock has outperformed its sector and generated a 20.03% return over the past year.

As of 18-Mar, IOL Chemicals & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at 73.76, reflecting an increase of 5.55 or 8.14%. This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 8% today and has shown a trend reversal after five consecutive days of decline. Additionally, the stock reached an intraday high of Rs 74.66, indicating strong intraday performance.<BR><BR>Investor participation has also increased, with delivery volume rising by 24.8% compared to the five-day average, suggesting growing interest among investors. Furthermore, the company reported positive financial results, with a significant growth in profit after tax (PAT) of 48.50% over the last six months and net sales reaching a record high of Rs 580.39 crore.<BR><BR>Despite some concerns regarding long-term growth and valuation, the stock has generated a return of 20.03% over the past year, outperforming the broader market. This combination of positive short-term performance, increased investor activity, and strong recent financial results contributes to the current rise in the stock price of IOL Chemicals & Pharmaceuticals Ltd.

View full answer

Why is IOL Chemicals & Pharmaceuticals Ltd falling/rising?

19-Mar-2026

As of 19-Mar, IOL Chemicals & Pharmaceuticals Ltd's stock price is declining at 72.83, down 1.26%. This decline is influenced by a negative chemicals sector performance, weak long-term growth prospects, and low domestic mutual fund participation, despite a strong past year return.

As of 19-Mar, IOL Chemicals & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 72.83, reflecting a change of -0.93 or -1.26%. This downward movement can be attributed to several factors. <BR><BR>Firstly, the overall performance of the chemicals sector has been negative, with a decline of -2.42%. Additionally, while the stock has outperformed its sector today by 1.21%, it is still facing challenges in the longer term. Over the past month, the stock has decreased by -2.19%, and year-to-date, it has fallen by -11.45%. <BR><BR>Despite a strong performance in the past year, where the stock generated a return of 14.15% compared to the market's 1.22%, its long-term growth prospects appear weak. The company's net sales have only grown at an annual rate of 0.38% over the last five years, and its operating profit has increased by just 7.22%. Furthermore, the stock is trading at a premium compared to its peers, with a Price to Book Value of 1.2, indicating an expensive valuation.<BR><BR>Investor sentiment may also be affected by the low participation from domestic mutual funds, which hold only 0.04% of the company, suggesting a lack of confidence in the stock's current price or business outlook. Overall, these factors contribute to the stock's current decline.

View full answer

Why is IOL Chemicals & Pharmaceuticals Ltd falling/rising?

20-Mar-2026

As of 20-Mar, IOL Chemicals & Pharmaceuticals Ltd's stock price is rising to Rs 74.26, driven by strong performance, increased investor interest, and positive financial results, including a 33.32% growth in PAT. The stock has outperformed its sector and generated a 13.81% return over the past year.

As of 20-Mar, IOL Chemicals & Pharmaceuticals Ltd's stock price is rising, currently at Rs 74.26, reflecting an increase of Rs 1.43 or 1.96%. This upward movement can be attributed to several factors. The stock has outperformed its sector by 2.2% today, indicating strong relative performance. Additionally, it reached an intraday high of Rs 75.67, which is a 3.9% increase from its previous close. <BR><BR>Investor participation has also increased, with a delivery volume of 11.62 lacs on 19 March, which is up by 13.53% compared to the 5-day average. This suggests growing interest and confidence among investors. Furthermore, the company reported positive financial results, with a PAT of Rs 92.85 crore, showing a growth of 33.32%, and net sales reaching their highest at Rs 580.39 crore for the quarter.<BR><BR>Despite some concerns regarding long-term growth and valuation, the stock has generated a return of 13.81% over the past year, significantly outperforming the broader market, which has seen a return of only 0.76%. The low debt-to-equity ratio and the stock's liquidity also contribute positively to its current performance. Overall, these factors indicate that the stock's price is rising due to strong recent performance, increased investor interest, and positive financial results.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor long term growth as Net Sales has grown by an annual rate of 0.38% and Operating profit at 7.22% over the last 5 years

 
2

With ROE of 6.6, it has a Expensive valuation with a 1.2 Price to Book Value

3

Despite the size of the company, domestic mutual funds hold only 0.04% of the company

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 2,156 Cr (Small Cap)

stock-summary
P/E

17.00

stock-summary
Industry P/E

36

stock-summary
Dividend Yield

1.40%

stock-summary
Debt Equity

-0.01

stock-summary
Return on Equity

6.62%

stock-summary
Price to Book

1.20

Revenue and Profits:
Net Sales:
580 Cr
(Quarterly Results - Dec 2025)
Net Profit:
21 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (1.4%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.68%
1.21%
-5.47%
6 Months
-32.37%
0.90%
-31.47%
1 Year
19.44%
1.57%
21.01%
2 Years
0.08%
6.46%
6.54%
3 Years
37.16%
15.08%
52.24%
4 Years
-2.62%
15.01%
12.39%
5 Years
-33.57%
17.71%
-15.86%

Latest dividend: 1 per share ex-dividend date: Feb-17-2026

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

Announcements stock-summary

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

20-Mar-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for NCVI Enterprises Ltd & PACs

Disclosure Under SEBI (Prohibition Of Insider Trading Regulation) 2015

20-Mar-2026 | Source : BSE

Disclosure under SEBI (PIT) Regulations

Disclosure Under SEBI (Prohibition Of Insider Trading Regulation) 2015

19-Mar-2026 | Source : BSE

Disclosure under SEBI (PIT) Regulations

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

IOL Chemicals & Pharmaceuticals Ltd has declared 50% dividend, ex-date: 17 Feb 26

stock-summary
SPLITS

IOL Chemicals & Pharmaceuticals Ltd has announced 2:10 stock split, ex-date: 11 Mar 25

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0.38%
EBIT Growth (5y)
7.22%
EBIT to Interest (avg)
10.16
Debt to EBITDA (avg)
0.52
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
1.12
Tax Ratio
26.76%
Dividend Payout Ratio
21.84%
Pledged Shares
0
Institutional Holding
2.11%
ROCE (avg)
9.06%
ROE (avg)
7.82%

Valuation key factors

Factor
Value
P/E Ratio
17
Industry P/E
36
Price to Book Value
1.20
EV to EBIT
12.98
EV to EBITDA
8.72
EV to Capital Employed
1.20
EV to Sales
0.94
PEG Ratio
0.61
Dividend Yield
1.40%
ROCE (Latest)
8.73%
ROE (Latest)
6.62%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 6 Schemes (0.02%)

FIIs

Held by 59 FIIs (2.08%)

Promoter with highest holding

Maya Devi Polycot Limited (21.54%)

Highest Public shareholder

Vasudeva Commercials Limited (4%)

Individual Investors Holdings

30.51%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 2.27% vs 2.87% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -31.33% vs -11.67% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "580.39",
          "val2": "567.53",
          "chgp": "2.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "57.28",
          "val2": "57.08",
          "chgp": "0.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.63",
          "val2": "3.48",
          "chgp": "4.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-11.21",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "20.58",
          "val2": "29.97",
          "chgp": "-31.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "9.87%",
          "val2": "10.06%",
          "chgp": "-0.19%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 8.86% vs -7.25% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 30.09% vs -41.34% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,119.22",
          "val2": "1,028.13",
          "chgp": "8.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "119.22",
          "val2": "92.68",
          "chgp": "28.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.71",
          "val2": "6.27",
          "chgp": "22.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "63.90",
          "val2": "49.12",
          "chgp": "30.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "10.65%",
          "val2": "9.01%",
          "chgp": "1.64%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 9.55% vs -4.75% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 21.29% vs -34.79% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,699.61",
          "val2": "1,551.43",
          "chgp": "9.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "176.50",
          "val2": "139.55",
          "chgp": "26.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "11.34",
          "val2": "10.73",
          "chgp": "5.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-11.21",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "84.48",
          "val2": "69.65",
          "chgp": "21.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "10.38%",
          "val2": "8.99%",
          "chgp": "1.39%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -2.51% vs -3.80% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -24.82% vs -3.39% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,079.21",
          "val2": "2,132.79",
          "chgp": "-2.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "202.30",
          "val2": "230.59",
          "chgp": "-12.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "14.76",
          "val2": "16.10",
          "chgp": "-8.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "101.07",
          "val2": "134.43",
          "chgp": "-24.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "9.73%",
          "val2": "10.81%",
          "chgp": "-1.08%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
580.39
567.53
2.27%
Operating Profit (PBDIT) excl Other Income
57.28
57.08
0.35%
Interest
3.63
3.48
4.31%
Exceptional Items
-11.21
0.00
Consolidate Net Profit
20.58
29.97
-31.33%
Operating Profit Margin (Excl OI)
9.87%
10.06%
-0.19%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 2.27% vs 2.87% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -31.33% vs -11.67% in Sep 2025

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
1,119.22
1,028.13
8.86%
Operating Profit (PBDIT) excl Other Income
119.22
92.68
28.64%
Interest
7.71
6.27
22.97%
Exceptional Items
0.00
0.00
Consolidate Net Profit
63.90
49.12
30.09%
Operating Profit Margin (Excl OI)
10.65%
9.01%
1.64%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 8.86% vs -7.25% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is 30.09% vs -41.34% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
1,699.61
1,551.43
9.55%
Operating Profit (PBDIT) excl Other Income
176.50
139.55
26.48%
Interest
11.34
10.73
5.68%
Exceptional Items
-11.21
0.00
Consolidate Net Profit
84.48
69.65
21.29%
Operating Profit Margin (Excl OI)
10.38%
8.99%
1.39%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 9.55% vs -4.75% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is 21.29% vs -34.79% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
2,079.21
2,132.79
-2.51%
Operating Profit (PBDIT) excl Other Income
202.30
230.59
-12.27%
Interest
14.76
16.10
-8.32%
Exceptional Items
0.00
0.00
Consolidate Net Profit
101.07
134.43
-24.82%
Operating Profit Margin (Excl OI)
9.73%
10.81%
-1.08%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -2.51% vs -3.80% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -24.82% vs -3.39% in Mar 2024

stock-summaryCompany CV
About IOL Chemicals & Pharmaceuticals Ltd stock-summary
stock-summary
IOL Chemicals & Pharmaceuticals Ltd
Small Cap
Pharmaceuticals & Biotechnology
IOL Chemicals and Pharmaceuticals Limited, incorporated in September, 1986 is a renowned company in the Active Pharmaceutical Ingredient (API) and specialty chemicals sectors. With substantive manufacturing capacities, the Company benefits from economies of scale and cost supremacy. Its extensive expertise in both API and specialty chemicals strengthens its business model and opens doors to diversified growth opportunities.
Company Coordinates stock-summary
Company Details
Trident Complex, Raikot Road Barnala Sangrur Punjab : 148101
stock-summary
Tel: 91-01679-244701-07
stock-summary
contact@iolcp.com
Registrar Details
Alankit Assignments Ltd , Alankit House , 2 E/21, Jhandewala Extension, New Delhi